Data presented at the European Society of Cardiology (ESC) Congress shows that Semaglutide 2.4 mg cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease
Cardiovascular diseases are consistently ranked among the leading causes of death in Kuwait. MOH Annual Health Reports document that circulatory diseases account for a substantial proportion of total mortality1
International estimates complement these findings. The World Heart Observatory (based on IHME data) reported that Kuwait recorded 4,201 deaths attributable to cardiovascular diseases in 2021, corresponding to an age-standardised mortality rate of 168 per 100,0002
Compared with tirzepatide, semaglutide 2.4 mg showed a significant 57% reduction in the risk for heart attack, stroke or death from any cause, in people with overweight or obesity and cardiovascular disease (CVD) who stayed on treatment3
Similarly, the study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the semaglutide 2.4 mg users compared with tirzepatide users in all treated people, regardless of any gaps in their treatment1
This study adds to growing evidence suggesting that the heart-protective benefits seen with semaglutide 2.4 mg are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments3
Kuwait, 3 September 2025 – Novo Nordisk today presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The STEER study investigated the risk of major adverse cardiovascular events (MACE) with semaglutide 2.4 mg compared with tirzepatide treatment in people with overweight or obesity and established CVD without diabetes.3
Compared with tirzepatide, semaglutide 2.4 mg showed a significant 57% greater risk reduction for heart attack, stroke and cardiovascular-related death or death from any cause, in people with overweight or obesity and CVD, who did not have any gaps in their treatment lasting more than 30 days. There were 15 (0.1%) of these cardiovascular events recorded with semaglutide 2.4 mg, and 39 events (0.4%) recorded with tirzepatide. The average follow-up duration was 3.8 months for the semaglutide 2.4 mg group and 4.3 months for the tirzepatide group.3
In all treated people, regardless of any gaps in their treatment, semaglutide 2.4 mg showed a significant 29% risk reduction for heart attack, stroke and death from any cause compared with tirzepatide (over an average follow-up of 8.3 months for semaglutide 2.4 mg and 8.6 months for tirzepatide).3
“Our landmark trial, SELECT, showed that Wegovy® is associated with a significant 20% risk reduction of cardiovascular events, backed up with even greater risk reductions in the real-world studies SCORE and STEER. The results are clear – STEER demonstrates that Wegovy® cuts the risk of heart attack, stroke or death by 57% compared to tirzepatide,” said Ludovic Helfgott, executive vice president and head of Product & Portfolio Strategy at Novo Nordisk. “This data confirms that semaglutide stands apart as the only available GLP-1-based medication with proven cardiovascular benefits for people living with obesity and cardiovascular disease, without diabetes.”
Additionally, in all treated people, regardless of any gaps in their treatment, people treated with semaglutide 2.4 mg experienced fewer events of heart attack, stroke and cardiovascular-related death, than people treated with tirzepatide.3
About obesity and cardiovascular disease
Every year, almost 21 million people die from CVD, which is the leading cause of disability and death worldwide.4 Obesity directly leads to cardiovascular morbidity, mortality and hospitalisation.3,4 While cardiovascular mortality has decreased over the past two decades, obesity-related cardiovascular deaths have increased significantly, with two in three obesity-related deaths being linked to CVD.7.8
About the real-world STEER study
Real-world studies of evidence gathered from actual patient experiences can complement randomised control trials, which are the gold standard for evaluating the safety and efficacy of a treatment.9 STEER was a retrospective, observational real-world study, evaluating the efficacy of semaglutide 2.4 mg versus tirzepatide for the prevention of MACE in US adults with overweight or obesity and established CVD with no prior history of diabetes, with a primary outcome measure of revised 5-point MACE (heart attack, stroke, hospitalisation for heart failure, coronary revascularisation, and death from any cause) and revised 3-point MACE (heart attack, stroke and death from any cause). Non-revised 5-point and 3-point MACE was also studied, which inclu
0 التعليقات :
إرسال تعليق